RxDoctor Payments Data

Vanessa Bajaj, APRN

Family · Elgin, ILNPI 1316546641

Payments from drug & device makers

$712in general payments, 2019–2025

Across 31 payments — averaging $22.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$145
  • Novo Nordisk$117
  • Welch Allyn$69
  • Amarin Pharma, Inc.$66
  • Mylan Specialty L.p.$43
  • Novartis$39
  • plus $233 from 11 others

What the payments were for

  • Food & beverage$54376%
  • Education$10014%
  • Other$6910%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$712 in reported general payments places this provider in the 65th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$21,529
Medicare patients
108
Services billed
401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide97$134,459
JardianceEmpagliflozin85$120,620
Breo ElliptaFluticasone/Vilanterol117$54,098
JanuviaSitagliptin Phosphate15$25,382
EliquisApixaban24$23,036
TrulicityDulaglutide18$20,042
XareltoRivaroxaban16$18,499
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$16,281
FarxigaDapagliflozin Propanediol11$14,100
Lantus SolostarInsulin Glargine,hum.Rec.Anlog95$12,276
Tresiba Flextouch U-200Insulin Degludec14$11,756
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$10,418
Incruse ElliptaUmeclidinium Bromide21$9,409
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,781
Atorvastatin Calcium590$5,516

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$117$134,45997 claims
GSKBreo Ellipta, Trelegy Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta$25$90,247183 claims
PfizerEliquis$23$23,03624 claims
Lilly USA, LLCTrulicity$25$20,04218 claims
AstraZenecaFarxiga$29$14,10011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,941 family providers in Illinois.

Other family in Elgin

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →